United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 150 ug - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precauti

United States - English - NLM (National Library of Medicine)

sandoz inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precauti

United States - English - NLM (National Library of Medicine)

preferrred pharmaeuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 137 ug - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precauti

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: - levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. - levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficie

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 25mcg - levothyroxine sodium 25mcg - thyroid agents

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 50mcg - levothyroxine sodium 50mcg - thyroid agents

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 75mcg - levothyroxine sodium 75mcg - thyroid agents

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 100mcg - levothyroxine sodium 100mcg - thyroid agents

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 125mcg - levothyroxine sodium 125mcg - thyroid agents

Canada - English - Health Canada

pharmascience inc - levothyroxine sodium - tablet - 150mcg - levothyroxine sodium 150mcg - thyroid agents